M
Medicofarma Biotech SA
WSE:MDB
Medicofarma Biotech SA
WSE:MDB
Price:
0.44
PLN
7.06%
Market Closed
Market Cap:
zł29.9m
Balance Sheet
Balance Sheet Decomposition
Medicofarma Biotech SA
Medicofarma Biotech SA
Balance Sheet Decomposition is not available for
Medicofarma Biotech SA
Medicofarma Biotech SA
Balance Sheet
Medicofarma Biotech SA
Medicofarma Biotech SA
Currency: PLN
| Dec-2015 | Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | Dec-2024 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||
| Cash & Cash Equivalents |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
0
|
|
| Cash |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
0
|
|
| Short-Term Investments |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Receivables |
0
|
0
|
0
|
1
|
1
|
0
|
1
|
1
|
0
|
1
|
|
| Accounts Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
0
|
1
|
|
| Other Receivables |
0
|
0
|
0
|
1
|
1
|
0
|
0
|
0
|
0
|
0
|
|
| Inventory |
0
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
0
|
0
|
|
| Other Current Assets |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
2
|
3
|
|
| Total Current Assets |
1
|
1
|
1
|
1
|
1
|
0
|
2
|
2
|
3
|
4
|
|
| PP&E Net |
0
|
0
|
0
|
0
|
0
|
0
|
13
|
13
|
12
|
11
|
|
| Intangible Assets |
0
|
0
|
0
|
0
|
0
|
0
|
2
|
2
|
0
|
0
|
|
| Note Receivable |
0
|
1
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Long-Term Investments |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Long-Term Assets |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Assets |
1
N/A
|
2
+5%
|
2
+13%
|
2
-7%
|
1
-15%
|
0
-71%
|
17
+4 092%
|
16
-2%
|
15
-9%
|
15
-2%
|
|
| Liabilities | |||||||||||
| Accounts Payable |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
1
|
|
| Accrued Liabilities |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
3
|
3
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Current Portion of Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Current Liabilities |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
0
|
|
| Total Current Liabilities |
1
|
0
|
1
|
1
|
1
|
1
|
1
|
3
|
4
|
4
|
|
| Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Deferred Income Tax |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Liabilities |
0
|
0
|
0
|
0
|
0
|
0
|
2
|
0
|
2
|
3
|
|
| Total Liabilities |
1
N/A
|
1
+11%
|
1
+24%
|
1
-22%
|
1
+15%
|
1
-11%
|
3
+313%
|
4
+47%
|
6
+54%
|
8
+35%
|
|
| Equity | |||||||||||
| Common Stock |
1
|
1
|
1
|
1
|
1
|
1
|
7
|
7
|
7
|
7
|
|
| Retained Earnings |
0
|
0
|
0
|
0
|
0
|
1
|
2
|
3
|
7
|
9
|
|
| Additional Paid In Capital |
0
|
0
|
0
|
0
|
0
|
0
|
9
|
9
|
9
|
9
|
|
| Total Equity |
1
N/A
|
1
+2%
|
1
+5%
|
1
+5%
|
1
-33%
|
0
N/A
|
14
N/A
|
13
-11%
|
9
-27%
|
7
-25%
|
|
| Total Liabilities & Equity |
1
N/A
|
2
+5%
|
2
+13%
|
2
-7%
|
1
-15%
|
0
-71%
|
17
+4 092%
|
16
-2%
|
15
-9%
|
15
-2%
|
|
| Shares Outstanding | |||||||||||
| Common Shares Outstanding |
7
|
7
|
7
|
7
|
7
|
7
|
68
|
68
|
68
|
68
|
|
Switch to:
Switch to:
See Also
Discover More
